UNSPSC 51241143: Travoprost ophthalmic solution

A prostaglandin analog indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

UNSPSC 51241143 Travoprost ophthalmic solution, a Commodity code, encompasses prescription pharmaceutical products for glaucoma and ocular hypertension treatment that state and local governments procure through cooperative purchasing vehicles and multi-source generic pharmaceutical contracts. The code covers branded and generic formulations of travoprost ophthalmic drops that supply public health facilities, correctional institutions, school-based clinics, and state Medicaid programs. State and local buyers access these products primarily through established pharmaceutical wholesaler distribution networks and cooperative agreements that aggregate purchasing across multiple jurisdictions to achieve volume discounts and standardized pricing. The issuing bodies pursuing this code include state health departments, state procurement offices administering cooperative purchasing alliances, and healthcare delivery systems serving state and local populations.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued a Request for Proposal on January 20, 2026 (S1070000015802) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products with a response deadline of March 26, 2026. The procurement covers participating state and local government facilities in Minnesota, Oregon, and other MMCAP member jurisdictions, requiring vendors to supply products through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC. Vendors must provide National Drug Codes (NDC), SKUs, UPCs, generic descriptions, strength, dosage forms, trade names, packaging configurations, and manufacturing locations, with all products available by May 15, 2026 and resulting agreements effective July 1, 2026. Evaluation criteria weight price competitiveness at 75 percent, with the remaining 25 percent distributed across fixed pricing, administrative compliance, EDI capability, and a 3 percent administrative fee commitment. Vendors must maintain workers' compensation and commercial general liability insurance of $5,000,000, network security and privacy liability of $2,000,000, and professional liability of $2,000,000, and must certify compliance with current Good Manufacturing Practices and the Drug Supply Chain Security Act.